dm+d

Unassigned

New Medicines

RevcoviAdenosine deaminase deficiency - severe combined immune deficiency (ADA-SCID) in adults and children

Information

Revcovi
New molecular entity
Chiesi
Chiesi

Development and Regulatory status

None
None
Launched
Yes
Jan 22Communication from Chiesi states - Revcovi does not have a marketing authorisation in the UK, and there are no plan for the future [5]
Nov 20Chiesi Global Rare Diseases announces that Chiesi Group has acquired Unikeris Limited,global marketer for Revcovi for the treatment of adenosine deaminase deficiency severe combined immunedeficiency (ADA-SCID), which was approved in the US in October 2018 and is available to patients in the EU through a named-patient access programme [4]
Feb 20Launched in US [3].
Oct 18Approved in US for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in paediatric and adult patients [1].

Category

PEGylated recombinant adenosine deaminase (rADA) enzyme therapy
ADA deficiency is very rare and is estimated to occur in approximately 1 in 200,000 to 1,000,000 newborns worldwide. Most individuals are diagnosed in the first 6 months of life. Without treatment, they do not usually survive past age 2 years. In 10 to 15% of cases, onset of immune deficiency occurs between 6 and 24 months of age (delayed onset) or in adulthood (late onset) [2].
Adenosine deaminase deficiency - severe combined immune deficiency (ADA-SCID) in adults and children
Intramuscular